Monday, 16 May 2011
Thursday, 12 May 2011
Monday, 9 May 2011
Six inspections at Hovione plants
Hovione facilities have undergone six successful GMP inspections in the last eight months. Sites in China and Portugal have been inspected by the Japanese PMDA; the Portuguese authorities inspected a site in April and the US FDA inspected the Loures site twice and New Jersey once.
PR Newswire
Q1 sales rise at Cambrex
Q1 2011 sales at Cambrex rose 9.8% to $61.7m compared to 2010. The company said the increase was due to higher sales of an API to a customer who resolved their supply chain disruption, higher volumes of generic APIs and increased volumes for a recently approved product.
Cambrex
Wednesday, 4 May 2011
Q1 contract revenues grow for AMRI
AMRI saw revenue growth in Q1 2011 driven by its contract manufacturing business. AMRI's development and small scale manufacturing revenue grew 24% to $10.5m and large scale manufacturing revenue grew 22% to $21.8m. The company has recently resumed GMP production at its Burlington, MA, facility and is working with the FDA to close out the Warning Letter as soon as possible.
AMRI
Tuesday, 3 May 2011
Carbogen-Amcis HPAPI facility meets standard
Carbogen-Amcis' new high potency API facility in Ahmedabad, India, has completed a containment performance evaluation. The facility, which is located on the Dishman Pharmaceuticals and Chemicals site, meets category IV standards.
Carbogen-Amcis
Thursday, 28 April 2011
Record sales for SAFC
Sales for Sigma-Aldrich's SAFC division grew by 16% to $180m in Q1 2011 compared to 2010. Kirk Richter, Sigma-Aldrich's Interim Chief Financial Officer, Vice President and Treasurer, said this growth at SAFC was partially due to continued strong demand by biopharma customers as sales of biological drugs continue to expand and also to strong demand for materials and precursors for semi-conductor and LED applications. Rakesh Sachdev, Chief Executive Officer, President and Director, said SAFC has a record level of booked orders for future delivery.
Seeking Alpha
Thursday, 21 April 2011
Strong Q1 for Albemarle
Net sales for Albemarle's fine chemicals business rose 30% to $177.3m in Q1 2011 and income rose 151% to $29.5m. The company said the improvement was due primarily to higher volumes and favourable pricing.
Business Week
Tuesday, 19 April 2011
Monday, 18 April 2011
Bakhu to acquire Phoenix site
Bakhu Pharma has acquired the IP assets of Phoenix Chemicals and is negotiating to purchase the Annan, Scotland, site from the administrators, RSM Tenon. The acquisition is expected to be completed in the next few weeks. Bakhu Pharma was incorporated on 31 March.
BBC
Wednesday, 13 April 2011
Dr Reddy's opens Chirotech expansion
Dr Reddy's has inaugurated the new headquarters for its Cambridge, UK, subsidiary Chirotech and plans to invest further in the site. Chirotech provides development services in the areas of chiral technologies, particularly chemocatalysis and biocatalysis.
Financial Times
Monday, 11 April 2011
Thursday, 7 April 2011
Wednesday, 6 April 2011
Monday, 4 April 2011
BASF increases prices
BASF is increasing the prices of its pharmaceutical excipients and APIs by at least 10% depending on the product group. The company said it is raising prices as a result of a rise in costs for raw materials, energy and labour.
BASF
Tuesday, 29 March 2011
Lonza invests in biomanufacturing
Lonza is to expand its biopharmaceutical manufacturing facility in Slough, UK. The company will invest £16m in a 6000m
The Engineer
Monday, 28 March 2011
Tuesday, 22 March 2011
Angel leases facility
Angel Biotechnology has leased a biomanufacturing facility in Cramlington, UK. The facility, which used to belong to Angel before it withdrew from the site in 2007, will expand Angel's manufacturing capacity five-fold. The company has leased the facility for 15 years and expects to be operational before the end of this year.
Sharecast
Monday, 21 March 2011
FDA and EMA start QbD pilot
The US FDA and the European Medicines Agency (EMA) will launch a three-year pilot program on 1 April to evaluate relevant quality data for new medicines. The Quality by Design (QbD) of pharmaceuticals involves an enhanced systematic and science-based approach to development and manufacturing, to better ensure product quality.
Pharma Times
Thursday, 17 March 2011
Siegfried sales grow in 2010
Siegfried reported sales growing 11% to CHF314.4m in 2010. The company said its API sales grew by 14.1% to CHF252.2m while sales of formulated drug products remained constant.
Chem Manager
Socma and EFCG call for FDA inspections
Socma’s Bulk Pharmaceutical Task Force (BPTF) and European Chemical Industry Council’s Fine Chemicals Group (EFCG) are calling on the FDA to mandate inspections of non-US API manufacturing sites. The two organisations said the FDA should collect a fee for the cost of inspection and the maintenance of a database of inspected sites.
Socma
Thursday, 10 March 2011
Wednesday, 9 March 2011
Tuesday, 8 March 2011
CIA and UKTI seek exhibitors for Chemspec Europe
The UK Chemical Industries Association and UK Trade & Investment are seeking companies for the UK pavillion at Chemspec Europe in June. Grants are available to potential exhibitors.
Contact Neil Harvey for more details
Monday, 7 March 2011
Helsinn to build cytotoxic plant
Helsinn Advanced Synthesis is to build a cytotoxic plant in Biasca, Switzerland. The CHF20m plant will have two production areas. One will have three reactor units capable of producing 10kg batches an the other will have larger reactor units to produce 20kg batches. Helsinn expects to begin commissioning projects for the plat in Q1 2012.
Cleanroom Technology
Wednesday, 2 March 2011
Monday, 28 February 2011
Fujifilm acquires Merck Biomanufacturing Network
Fujifilm has acquired Merck's Biomanufacturing network for $490m. The network consists of the former Avecia facility in Billingham, UK, and Diosynth RTP in Research Triangle Park, NC. Merck has committed to certain continued development and manufacturing activities with Fujifilm.
Bloomberg
Samsung to establish biomanufacturing jv with Quintiles
Samsung and Qunitiles have established a joint venture to provide biopharmaceutical contract manufacturing services in South Korea. Samsung will own 90% of the joint venture company and Quintiles 10%. The jv company will construct its biopharmaceutical manufacturing plant in the Incheon Free Economic Zone in South Korea and be equipped with cutting-edge technologies and 30,000L of mammalian cell culture bioreactor capacity. Groundbreaking is expected in the first half of 2011 and full-scale operation is expected to commence in April 2013.
Bloomberg Business Week
Wednesday, 23 February 2011
Carbogen Amcis to restructure
Carbogen Amcis plans to restructure its three sites in Sqitzerland. Following the restructuring, the Aarau site will focus more strongly on development; the Hunzenschwil site on the pilot production of early phase projects and the Bubendorf site on large-volume production and the manufacturing of highly active agents. The company said that 60 of its 350 staff will be made redundant.
Carbogen Amcis
Monday, 21 February 2011
Alphora to invest $4m
Alphora is investing $4m during 2011 expanding its facilities and capabilities for API technology development. The company said the expansion is to meet growing demand from customers. The company, which recently increased its R&D capacity by 50% by securing new research facilities, is adding isolation technology for its high potency API development services and will add a fourth cGMP kilo lab.
Contract Pharma
Thursday, 17 February 2011
Pfenex links with Boehringer Ingelheim
Pfenex will use its Pfenex Expression Technology to engineer production strains and processes for Boehringer Ingelheim's proprietary molecules, and molecules from Boehringer Ingelheim's contract manufacturing customers. The companies said the partnership will enable preclinical and clinical development to progress much more quickly and efficiently.
San Diego Union-Tribune
Wednesday, 16 February 2011
Profits fall at Dishman
Dishman Pharmaceuticals reported a its net profits fell 94% during its Q3 ended 31 December 2010, while turnover increased 4% to $51m. The company said performance was affected by a lower-than-expected performance at its Carbogen Amcis subsidiary.
Business Standard
FDA to outsource foreign plant inspections
The US FDA is looking to increase the number of overseas plant inspections through the use of third-party inspectors, according to John Taylor, the agency’s acting principal deputy commissioner. The agency is looking to reduce the average of nine yeas between plant inspections overseas.
Bloomberg
Monday, 14 February 2011
Record quarter for SAFC
Sigma-Aldrich's SAFC business unit reported recede sales of $171m in Q4 2010. Sales for the unit in the full year 2010 were $647m up 9% on 2009. Rakesh Sachdev, Sigma-Aldrich cep, president and director said the company is "pleased with the higher level of SAFC's booked orders for future delivery as that is an indicator of future growth for that business". He added that "we expect our SAFC Pharmaceutical business to improve further in 2011" as a result of new added capacity in Wisconsin and California. Additionally, Sachdev said that despite the challenges facing the SAFC Custom Pharma business in Europe the SAFC Custom Pharma business in the US and the international markets is doing quite well.
Seeking Alpha
Wednesday, 9 February 2011
Boehringer to manufacture Elan antibodies
Boehringer Ingelheim will provide technical development, clinical manufacturing and all related regulatory filing support services for antibodies discovered by Elan.
RTE
Tuesday, 8 February 2011
Ampac adds new facility
Ampac Fine Chemicals has added a second semi-works facility in Rancho Cordova, CA. The company said the facility was part of several capital improvements in progress during 2011 and became fully operational in January. This facility offers a state of the art, remotely operable facility that is designed to safely run hydrogenations, hazardous chemistry and potent compound processes.
Ampac
Monday, 7 February 2011
Large scale manufacturing underpins AMRI revenues
Contract revenues rose 4% at AMRI to $163.2m in 2010. Of this revenues for development/small scale manufacturing fell 4% to $36.5m and revenues for large scale manufacturing grew 13% to $71.0m.
Albany Business Review
Pharma products boost Codexis revenues
Codexis' revenues grew 29% to $107.1m in 2010. The growth was driven by a 77% increase in sales of pharmaceutical products, from $18.6m to $32.8m, and increases in collaborative R&D and government grants. The company reported a net loss of $8.5m a reduction on the loss of $20.3m in 2009. Codexis forecasts revenues of over $120m in 2011.
Codexis
ICIG to buy Genzyme API unit
International Chemical Investors Group is to acquire Genzyme's API manufacturing unit. ICIG will maintain operations at Genzyme's Liestal, Switzerland, facility and rename the unit Corden Pharma Switzerland LLC. As part of the agreement, ICIG will enter into a five-year supply contract to provide Genzyme with materials needed for the production of eliglustat tartrate, an investigational treatment for Gaucher disease Type 1 that is currently in phase 3 clinical trials. Additionally, ICIG will supply materials needed for the manufacture of other treatments in earlier stages of development. Financial terms for the agreement, expected to close during Q1, were not disclosed.
Boston Globe
Wednesday, 2 February 2011
Fine chems grow for Johnson Matthey in Q3
Q3 sales at Johnson Matthey's Fine Chemicals Division improved 10% over last year. The company said sales of APIs remained good, particularly in North America, and the performance of its Pharmaceutical Services business continued to improve.
Johnson Matthey
Monday, 31 January 2011
Recipharm sells Oxford facility
Recipharm has sold its decommissioned manufacturing facility in Oxford, UK, to Oxford BioMedica for £1.9m. Recipharm acquired the facility when it bought Cobra Biologics in 2010. Oxford BioMedica will recommission the plant over the next 12 months to provide production capacity for its proprietary LentiVector gene delivery technology.
Recipharm
New contract as Angel raises cash
Angel Biotechnology will provide pre-GMP services for Pathfinder Cell Therapy's novel cell therapy. Additionally, the company has raised £1.9m in a placing of 553,435,720 ordinary shares.
Angel Biotechnology
Angel Biotechnology
Wednesday, 26 January 2011
Lonza robust in 2010
Lonza reported sales in its custom manufacturing business unit increase almost 2% to CHF1.4bn in 2010. The company said this growth was driven primarily by improved capacity utilisation in large-scale biological manufacturing as a result of new product introductions, especially in the second half of the year. The company has almost 300 products in its chemical pipeline and about 260 in its biological pipeline and reported capacity utilisation rates of around 75% for both businesses. Lonza also said that the build-out of its large scale mammalian biopharmaceutical facility in Singapore is on track, with start-up targeted in Q3 2011. Additionally, TL Biopharmaceuticals, its joint venture with Teva, has commenced a clinical phase-I trials with its first biosimilar product.
Looking forward, Lonza expects to continue to benefit from increased outsourcing of manufacturing and development by pharmaceutical and biotechnology companies, which combined with stronger product pipelines, improved capacity utilisation and a more appropriate cost base, provides the company with a good platform for a solid performance in 2011.
Reuters
